The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Intra-tumour heterogeneity: a looking glass for cancer?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Research works printed but not linked: 2
- Heppner, G. H. Cancer cell societies and tumor progression. Stem Cells 11, 199–203 (1993). · doi:10.1002/stem.5530110306
- Miller, B. E., Machemer, T., Lehotan, M. & Heppner, G. H. Tumor subpopulation interactions affecting melphalan sensitivity in palpable mouse mammary tumors. Cancer Res. 51, 4378–4387 (1991).
Cited by
Items 101–117 of 117
Tumor organoid models in precision medicine and investigating cancer-stromal interactions
Xu, R., Zhou, X., Wang, S., & Trinkle, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107668 · Cited by 134
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery
Jurczyk, M., Jelonek, K., Musiał-Kulik, M., Beberok, A., Wrześniok, D., & Kasperczyk, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030326 · Cited by 133
Bai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107
Single-cell mutational profiling and clonal phylogeny in cancer
Potter, N. E., Ermini, L., Papaemmanuil, E., Cazzaniga, G., Vijayaraghavan, G., Titley, I., Ford, A., Campbell, P., Kearney, L., & Greaves, M. (2013) · Genome Research · doi:10.1101/gr.159913.113 · Cited by 107
“Not only do cancers of a similar type differ in their genomic landscapes—indeed, each is unique—but intraclonal genetic and phenotypic diversity is an inherent feature of this disease (Marusyk et al. 2012).”
BackgroundLung cancer stem cell markers as therapeutic targets: An update on signaling pathways and therapies
Zheng, Y., Wang, L., Yin, L., Yao, Z., Tong, R., Xue, J., & Lu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.873994 · Cited by 97
Zhou, M., Hall, L., Goldgof, D., Russo, R., Balagurunathan, Y., Gillies, R., & Gatenby, R. (2014) · Translational Oncology · doi:10.1593/tlo.13730 · Cited by 97
Zhou, J. X., Taramelli, R., Pedrini, E., Knijnenburg, T., & Huang, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09307-w · Cited by 85
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis
Gross, A. C., Cam, H., Phelps, D. A., Saraf, A. J., Bid, H. K., Cam, M., London, C. A., Winget, S. A., Arnold, M. A., Brandolini, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99791 · Cited by 82
de Maar, J. S., Sofias, A. M., Porta Siegel, T., Vreeken, R. J., Moonen, C., Bos, C., & Deckers, R. (2020) · Theranostics · doi:10.7150/thno.38625 · Cited by 71
Han, B., Qu, C., Park, K., Konieczny, S. F., & Korc, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.003 · Cited by 53
Endo, H., Okami, J., Okuyama, H., Nishizawa, Y., Imamura, F., & Inoue, M. (2017) · Oncogene · doi:10.1038/onc.2016.431 · Cited by 50
Polk, S. L., Choi, J. W., McGettigan, M. J., Rose, T., Ahmed, A., Kim, J., Jiang, K., Balagurunathan, Y., Qi, J., Farah, P. T., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i24.3458 · Cited by 48
Computational estimation of quality and clinical relevance of cancer cell lines
Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31
Zhu, Y., Li, J., Lin, X., Huang, X., & Hoffmann, M. R. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01615 · Cited by 18
The Lipid Droplet Protein DHRS3 Is a Regulator of Melanoma Cell State
Johns, E., Ma, Y., Louphrasitthiphol, P., Peralta, C., Hunter, M. V., Raymond, J. H., Molina, H., Goding, C. R., & White, R. M. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13208 · Cited by 9
McMahon, N. P., Solanki, A., Wang, L. G., Montaño, A. R., Jones, J. A., Samkoe, K. S., Tichauer, K. M., & Gibbs, S. L. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01589-x · Cited by 8
Cha, J., & Kim, P. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.018 · Cited by 8
Metadata
- Authors
- Marusyk, A., Almendro, V., & Polyak, K.
- Venue
- Nature Reviews Cancer
- Published
- 2012-04-19
- Volume
- 12
- Issue
- 5
- Pages
- 323-334
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1987012261
- Cited by
- 2,000
- References
- 108
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.